APA (7th ed.) Citation

Long, G., Arance, A., Mortier, L., Lorigan, P., Blank, C., Mohr, P., . . . Ibrahim, N. (2022). Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: Analysis from KEYNOTE-006. Annals of Oncology, 33(2), 204. https://doi.org/10.1016/j.annonc.2021.10.010

Chicago Style (17th ed.) Citation

Long, G.V, et al. "Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab Treatment in Patients with Advanced Melanoma: Analysis from KEYNOTE-006." Annals of Oncology 33, no. 2 (2022): 204. https://doi.org/10.1016/j.annonc.2021.10.010.

MLA (9th ed.) Citation

Long, G.V, et al. "Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab Treatment in Patients with Advanced Melanoma: Analysis from KEYNOTE-006." Annals of Oncology, vol. 33, no. 2, 2022, p. 204, https://doi.org/10.1016/j.annonc.2021.10.010.